Can we improve the performance of live oral rotavirus vaccines?
|
|
- Brice Hill
- 6 years ago
- Views:
Transcription
1 Can we improve the performance of live oral rotavirus vaccines? Duncan Steele 9 th International Rotavirus Symposium 2 & 3 August 2010, Johannesburg, South Africa
2 Vaccine efficacy against severe rotavirus GE in the first year of life, by region Region Vaccine Countries VE 95% CI Africa 1 Rotarix TM Malawi, South Africa Africa 2 RotaTeq Ghana, Kenya, Mali Asia 3 RotaTeq Bangladesh, Vietnam , , , Madhi & Cunliffe et al. NEJM 2010; 362: ; 2 Armah et al. Lancet 2010 Aug6 epub; 3 Zaman et al. Lancet 2010 Aug6 epub
3 Lives saved How does this efficacy translate into impact on a population level? 2,500,000 Estimates of cumulative impact of rotavirus vaccines, ,000,000 60% efficacy 1,500,000 1,000, ,000 0 Conservative estimates including vaccine efficacy; immunization coverage; graduated uptake by countries Efficacy 3 Source: GAVI Investment Case, 2006; Atherly D et al. J Infect Dis 2009.
4 Determinants of responses to oral vaccines in developing countries Experience with several oral vaccines have shown that the immune responses are not as robust or consistent when given to children in developing countries. Nutrition protein calorie deficiency / micronutrient deficiency Maternal antibody transplacental antibody / breast milk Gut enteropathy or intestinal damage Bacterial small bowel overgrowth Intestinal parasitic infections Interference from enteric microbes Vaccine characteristics antigenicity vs. reactogenicity; # doses; age of administration, etc. 4 Source: Sack DA et al. Ann Nestle 2008; 66: 71-79
5 Does maternal antibody play a role? Higher background levels of maternal antibody adversely affects immune response to rotavirus vaccines An inverse correlation was observed in three studies of maternal antibody levels and the vaccine sero-response Maternal antibody levels vary according to rotavirus season Maternal antibody wanes over time 5
6 GMC of Transplacental Rotavirus IgG in Mexico in Responders and Non-Responders Sero-response rate was 65.4% Status N GMC Responder ( ) Non-Responder ( ) 6 R Ward and G Ruiz-Palacios (unpublished data)
7 GMC of Transplacental Rotavirus IgG in South Africa in Responders and Non-Responders Group * Status N GMC Before 2002 RV season Responder ( ) Non-Responder ( ) After 2002 Responder ( ) RV season Non-Responder ( ) * Response rate before 2002 RV season: 42.6% Response rate after 2002 RV season: 55.6% 7 R Ward and D Steele (unpublished data)
8 8 Maternal antibody probably plays a role in the poor immune response seen in infants in developing countries, but programmatic solutions are unlikely
9 What do we know of the role of breast milk? Breast milk contains anti-rotavirus antibodies Breast milk can neutralize rotavirus titre in vitro Breast milk contains other anti-rotavirus factors eg. lactadherins Studies are ongoing to evaluate the effect of delaying breast feeding at the time and point of vaccination Exclusive breastfeeding is advocated by WHO may be difficult to implement programmatically 9 Moon SS et al. P Infect Dis J 2010; Newbury DS et al. Lancet 1998
10 Effects of the dose regimen and number of doses Current WHO recommendations: 2-dose vaccine at DPT1 and DPT2 Last dose of vaccine by 32 weeks of age 10
11 What is the effect of the number of doses on immunogenicity? South Africa Malawi >=20 U/ML GMC >=20 U/ML GMC 2 dose N=70/36 (48-69) (37-94) (30-64) (26-102) 3 dose N=66/49 (54-78) (56-157) (42-72) (36-109) Pooled N=136/85 (53-70) (53-104) (42-64) (38-88) Placebo 11.6 < N=69/42 (5-22) (25-57) (21-68) 11 Madhi & Cunliffe et al. NEJM 2010; 362:
12 What is the effect of number of doses on rotavirus vaccine efficacy? Countries Africa South Africa Malawi 2 dose (10,14 wks) ( ) ( ) ( ) 3 dose (6,10,14 wks) ( ) ( ) ( ) Pooled vaccine 61.2 ( ) 76.9 ( ) 49.4 ( ) 12 Madhi & Cunliffe et al. NEJM 2010; 362:
13 Immunogenicity of rotavirus vaccine is lower at younger ages Countries Rotarix Schedule Anti-rotavirus IgA antibody Seropositivity Rates Vietnam Philippines South Africa 9, 13* 62.5 (54; 71) 13, 17* 81.1 (73; 88) 6, (53; 69) 10, (65; 80) 6, ** (23; 50) 10, ** (43; 76) *median age **sero-conversion 13 Steele AD et al. Vaccine 2008
14 Coverage What is effect of age of administration on rotavirus vaccines? wk 12 wk 70% 57% 24 wk 36 % 8 m 54% DTP1 DTP Age in months Clark A et al. Lancet WHO recommends the last dose of rotavirus vaccine by 32 weeks of age WHO / UNICEF advocates on time immunization so it is counter-productive to hope for delayed vaccination in the infants most in need
15 Should we think of a booster dose of rotavirus vaccine? Waning of protection was observed with both vaccines in the second year of life in developing country populations Should we consider a booster dose of vaccine with measles at 9 months of age? Safety of co-administration with measles vaccine Evaluate non-interference with measles vaccine immune response Lower disease burden in second year of life Safety concerns for intussusception and age of administration at 9 months? 15
16 Supplementation with micronutrients and / or probiotics Rhesus Rotavirus Vaccine immunogenicity study. Lactobacillus casei GG given at vaccine administration at 4 months of age; then 2x daily for 5 days at home IgA sero-conversion was more frequent in probiotic group compared with placebo group IgA, IgM and IgG GMT were all (non-significantly) higher. OPV trial in adults with 2 different Lactobaccilus spp. Neutralizing antibody levels were higher in the probiotic groups 16 Source: Isolauri E et al. Vaccine 1995; De Vreese M et al. Euro J Nutr 2005
17 Rotavirus Research Agenda AVI TAC Special Studies Ongoing studies: 17 Effectiveness studies in Nicaragua, Bolivia and South Africa Post-marketing studies for vaccine safety in Latin America Modeling of transmission dynamics of rotavirus Population effectiveness of vaccination in Bangladesh Evaluation of an additional dose of Rotarix in Pakistan Evaluation of withholding of breastfeeding in Pakistan Strain diversity and molecular evolution analysis Planned studies: Age of administration of Rotarix Booster dose with measles
18 Lives saved Introduction of rotavirus vaccines today is a priority 2,500,000 Estimates of cumulative impact of rotavirus vaccines, ,000, million lives 1,500,000 1,000, , Efficacy Rotavirus vaccines reduce all cause diarrhoea hospitalizations by ~25% Rotavirus vaccines reduce diarrhoeal mortality Rotavirus vaccines show dramatic impact and indirect effects 18
Rotavirus vaccines: Issues not fully addressed in efficacy trials
Rotavirus vaccines: Issues not fully addressed in efficacy trials TM Umesh D. Parashar Lead, Viral Gastroenteritis Team CDC, Atlanta, USA uparashar@cdc.gov 1 Two New Rotavirus Vaccines Licensed in 2006
More informationImpact of withholding breastfeeding around the time of Rotarix vaccination on the immunogenicity of Rotarix vaccine A Randomized Trial
Impact of withholding breastfeeding around the time of Rotarix vaccination on the immunogenicity of Rotarix vaccine A Randomized Trial S. Asad Ali, MD, MPH Department of Pediatrics and Child Health Aga
More informationVaccines against Rotavirus & Norovirus. Umesh D. Parashar CDC, Atlanta, GA
TM Vaccines against Rotavirus & Norovirus Umesh D. Parashar CDC, Atlanta, GA 1 Rotavirus is the Leading Cause Of Severe Diarrhea in Children
More informationValue of post-licensure data to assess public health value Example of rotavirus vaccines
Value of post-licensure data to assess public health value Example of rotavirus vaccines TM Umesh D. Parashar Lead, Viral Gastroenteritis Team CDC, Atlanta, USA uparashar@cdc.gov 1 Two New Rotavirus Vaccines
More informationRotavirus Vaccines. Gagandeep Kang Christian Medical College Vellore
Rotavirus Vaccines Gagandeep Kang Christian Medical College Vellore Rotavirus disease burden Rotavirus vaccines and candidates Performance of vaccines in developed and developing countries Longitudinal
More informationUpdates on Rotasiil development
Updates on Rotasiil development 13 th International Rotavirus Symposium Minsk, Belarus 30 August 2018 Dr Sajjad Desai MD Serum Institute of India Pvt Limited, Pune Rotasiil Bovine-human reassortant strains
More informationBangladesh: How to move from data to implementation. K. Zaman, MBBS, PhD Senior Scientist and Epidemiologist icddr,b
Bangladesh: How to move from data to implementation K. Zaman, MBBS, PhD Senior Scientist and Epidemiologist icddr,b Rotavirus in Bangladesh Estimated 2.4 million cases of rotavirus diarrhoea annually in
More informationROTAVIRUS VACCINES. Virology
ROTAVIRUS VACCINES Virology Rotavirus is a triple-layers viral particle belonging to the Reoviridae family. It contains 11 segments of double-stranded RNA, of which 6 are structural and 5 are non-structural
More informationCorrelates of efficacy for human rotavirus vaccines Value of anti-rotavirus immunoglobulin A antibody concentrations
Correlates of efficacy for human rotavirus vaccines Value of anti-rotavirus immunoglobulin A antibody concentrations Brigitte Cheuvart, Kathleen M. Neuzil, Duncan Steele, Nigel Cunliffe, Shabir A. Madhi,
More informationNew and Underused Vaccines, Rotavirus
New and Underused Vaccines, Rotavirus George Armah Noguchi Memorial Institute for Medical research University of Ghana 10th Annual African Vaccinology Course (VACFA) Cape town, South Africa 10 th to 14
More informationdeveloping countries in Latin America?
. How have rotavirus vaccines worked in developing countries in Latin America? Brendan Flannery, Pan American Health Organization, Brazil and Lúcia De Oliveira, Immunization Unit/FCH, Washington, DC 9th
More informationRotavirus: WHO Global Recommendations, Policy, and Surveillance
Rotavirus: WHO Global Recommendations, Policy, and Surveillance 9 th International Rotavirus Symposium 2 August 2010 Mary Agócs, MD, MSc Department of Immunization, Vaccines & Biologicals From 1999 2009:
More informationShabir A. Madhi. Progress and Challenges of Immunization Contributing Toward Attaining the MDG Goal to Reduce under-5 Childhood Mortality.
Shabir A. Madhi Progress and Challenges of Immunization Contributing Toward Attaining the MDG Goal to Reduce under-5 Childhood Mortality. National Institute for Communicable Diseases & University of Witwatersrand,
More informationDr Michelle Groome MBBCh (Wits) DCH(SA) MScMed (Epi & Biostats) Department of Science and Technology/National Research Foundation: Vaccine
Dr Michelle Groome MBBCh (Wits) DCH(SA) MScMed (Epi & Biostats) Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases; Medical Research Council: Respiratory and
More informationAssessing the Evidence for Potential Benefits and Risks of Removing the Age Restrictions for Rotavirus Vaccination
Assessing the Evidence for Potential Benefits and Risks of Removing the Age Restrictions for Rotavirus Vaccination Manish Patel SAGE Geneva 12 April 2012 1 Overview! Update new inputs for benefit risk
More informationA Human Rotavirus Vaccine
7th International Rotavirus Symposium Lisbon, Portugal, 12-13 June 2006 A Human Rotavirus Vaccine Dr. Béatrice De Vos GlaxoSmithKline Biologicals Rixensart, Belgium Rotarix is a trade mark of the GlaxoSmithKline
More informationRotavirus Vaccines for Infants in Developing Countries in Africa and Asia: Considerations from a World Health Organization Sponsored Consultation
SUPPLEMENT ARTICLE Rotavirus Vaccines for Infants in Developing Countries in Africa and Asia: Considerations from a World Health Organization Sponsored Consultation A. Duncan Steele, 1,2 Manish Patel,
More informationThe Pentavalent Rotavirus Vaccine, RotaTeq : From Development to Licensure and Beyond
The Pentavalent Rotavirus Vaccine, RotaTeq : From Development to Licensure and Beyond Max Ciarlet, PhD Vaccines Clinical Research Department Merck Research Laboratories North Wales, Pennsylvania, United
More informationUpdate on Pentavalent Human-Bovine Rotavirus Vaccine. Michelle Goveia, MD, MPH Medical Director MSD Vaccines India, September 2014
Update on Pentavalent Human-Bovine Rotavirus Vaccine Michelle Goveia, MD, MPH Medical Director MSD Vaccines India, September 2014 Outline Characteristics of RotaTeq and its worldwide use Recent data evaluating
More informationRotarix : Global Efficacy against Severe RV GE due to G1 and non-g1 (G2, G3, G4, G9) RV Types
Rotarix : Global Efficacy against Severe RV GE due to G1 and non-g1 (G2, G3, G4, G9) RV Types 8 th International Rotavirus Symposium Istanbul, 3 rd June 2008 Dr. Norman Begg, Vice President, Clinical Development
More informationRoger I. Glass, M.D., Ph.D. Director, Fogarty International Center Associate Director for International Research, NIH
Rotavirus Vaccines: Prioritization for Introductions- National & International Case Studies Fondation Merieux Conference Center November 27, 2012 Roger I. Glass, M.D., Ph.D. Director, Fogarty International
More informationAlternative Rotavirus Vaccine Candidates: Why should we bother?
Alternative Rotavirus Vaccine Candidates: Why should we bother? Duncan Steele Initiative for Vaccine Research, WHO 7 th International Rotavirus Symposium 12-13 June 2006, Lisboa, Portugal Rotavirus Vaccines
More informationDr. Bernd Benninghoff GSK Vaccines, GML Global Medical Affairs Director
ROTARIX the human rotavirus vaccine: -is applied in a 2-dose schedulecompletes the course at the earliest possible age, prevents morbidity and mortality from RV GE regardless of the circulating strains
More informationWill live oral vaccines work in children in the developing world? Martin Friede Ph.D. Initiative for Vaccine Research
Will live oral vaccines work in children in the developing world? Martin Friede Ph.D. Initiative for Vaccine Research Estimated global distribution of the 600,000 annual deaths caused by rotavirus 2 1
More informationACTIVE SURVEILLANCE FOR INTUSSUSCEPTION IN A PHASE III EFFICACY TRIAL OF AN ORAL MONOVALENT ROTAVIRUS VACCINE IN INDIA.
ACTIVE SURVEILLANCE FOR INTUSSUSCEPTION IN A PHASE III EFFICACY TRIAL OF AN ORAL MONOVALENT ROTAVIRUS VACCINE IN INDIA. Sangeeth Rajkumar Christian Medical College, Vellore ORV 116E Phase III trial plan
More informationDIARRHEAL DISEASE MESSAGING
DEFEATDD.ORG DIARRHEAL DISEASE MESSAGING PATH developed these messages for use by anyone interested in communicating the impact of diarrhea on the health and development of children and families around
More informationI mun u i n s i atio i n o n u p u d p a d te
Immunisation update Brian Eley Paediatric Infectious Diseases Unit Red Cross War Memorial Children s Hospital Department of Paediatrics and Child Health University of Cape Town Immunisation schedules,
More informationGlobal Immunization Vision and Strategies (GIVS) Vaccine Tender , Pretender Meeting, Copenhagen December 2008
Global Immunization Vision and Strategies (GIVS) 2006-2015 Vaccine Tender 2010-2012, Pretender Meeting, Copenhagen 10-11 December 2008 Dr Ahmed Magan & Dr Osman David Mansoor Programme Division UNICEF
More informationFrom development to delivery: Decision-making for the introduction of a new vaccine
From development to delivery: Decision-making for the introduction of a new vaccine Prince Mahidol Award Conference Bangkok, Thailand 1-2 February 2007 Dr. J.M. Okwo-Bele Department of Immunization, Vaccines
More informationMaternal Immunization: Unique considerations of public health value of vaccines given to pregnant women
Maternal Immunization: Unique considerations of public health value of vaccines given to pregnant women Estimating the full public health value of vaccines Kathleen M. Neuzil, MD, MPH Professor of Medicine
More informationWhy is surveillance important after introducing vaccines?
Why is surveillance important after introducing vaccines? Dr Michael Edelstein Immunisation Department, National Infections service Public Health England @epi_michael BSAC Spring conference, 12 th March
More information8 th INTERNATIONAL ROTAVIRUS SYMPOSIUM
PROCEEDINGS FROM THE 8 th INTERNATIONAL ROTAVIRUS SYMPOSIUM June 3 4, 2008 Istanbul, Acknowledgements The Symposium Organizing Committee wishes to thank the following organizations for support of the 8th
More informationDistributional Effects of Rotavirus Vaccination in Low-income Countries
Distributional Effects of Rotavirus Vaccination in Low-income Countries Rick Rheingans, PhD Emerging Pathogens Institute University of Florida 10 th International Rotavirus Symposium Bangkok, Thailand
More informationASSESSING THE VALUE OF VACCINE BEYOND EFFICACY AND SAFETY
ASSESSING THE VALUE OF VACCINE BEYOND EFFICACY AND SAFETY Bradford D. Gessner, MD Agence de Médecine Preventive First Regional Dengue Symposium Rio de Janeiro, Brasil November 3-4, 2015 BURDEN CONCEPTS
More informationNo of studies/starting rating 8 studies-all RCTs (32,854 participants) 2 4. Inconsistency none 0. Indirectness none 0. Imprecision none 0
Grading of scientific evidence Tables 1 4: Does RV1and RV5 induce protection against rotavirus morbidity and mortality in young children both in low and highmortality settings? Table 1: EFFECTIVENESS OF
More informationWHO Rotavirus Vaccine Update Dr. Fatima Serhan WHO/FWC/IVB/EPI
WHO Rotavirus Vaccine Update 2012 Dr. Fatima Serhan WHO/FWC/IVB/EPI WHO estimates that 453 000 child deaths occurred during 2008 due to rotavirus infection 41057 32653 39144 98621 82% of these deaths occurred
More informationCould a combination of OPV & IPV accelerate wild type poliovirus eradication? Nicholas Grassly
Could a combination of OPV & IPV accelerate wild type poliovirus eradication? Nicholas Grassly SAGE working group on IPV (est. Aug 2008) SAGE Members Elizabeth Miller, Chair Hyam Bashour Peter Figueroa
More informationUpdate from the GAVI Alliance Seth Berkley, MD Chief Executive Officer
Update from the GAVI Alliance Seth Berkley, MD Chief Executive Officer SAGE meeting Geneva, 8-10 November 2011 Topics to cover Update on new vaccine introduction Introductions New approvals Co-financing
More informationRotarix TM. Rotavirus vaccine. 1 dose (1.5 ml) contains: Live attenuated human rotavirus RIX4414 strain
Rotarix TM Rotavirus vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (1.5 ml) contains: Live attenuated human rotavirus RIX4414 strain not less than 10 6.0 CCID50 PHARMACEUTICAL FORM Oral suspension.
More informationA Briefing Paper on Rotavirus
COMMON VIRUS AND SENSELESS KILLER: A Briefing Paper on Rotavirus DIARRHEA KILLS. MOTHERS IN THE WORLD S POOREST COUNTRIES KNOW THIS ALL TOO WELL. It s a fact few people in wealthier nations realize. Rotavirus
More informationROTAVIRUS COMMON, SEVERE, DEVASTATING, PREVENTABLE [ ] THE LATEST EVIDENCE & WHAT S NEEDED TO STOP ILLNESSES AND DEATHS
ROTAVIRUS COMMON, SEVERE, DEVASTATING, PREVENTABLE [ ] THE LATEST EVIDENCE & WHAT S NEEDED TO STOP ILLNESSES AND DEATHS ROTACOUNCIL.ORG Table of contents Introduction...4 What is rotavirus?... 5 Vaccines:
More informationin control group 7, , , ,
Q1 Rotavirus is a major cause of severe gastroenteritis among young children. Each year, rotavirus causes >500,000 deaths worldwide among infants and very young children, with 90% of these deaths occurring
More informationSUPPLEMENT ARTICLE. of Africa and Asia. The highest rates of rotavirus-associated mortality occur in sub-saharan Africa, where
SUPPLEMENT ARTICLE Comparison of 2 Different Regimens for Reactogenicity, Safety, and Immunogenicity of the Live Attenuated Oral Rotavirus Vaccine RIX4414 Coadministered with Oral Polio Vaccine in South
More informationCommon Virus and Senseless Killer: A Briefing Paper on Rotavirus
Common Virus and Senseless Killer: A Briefing Paper on Rotavirus Diarrhea kills. Mothers in the world s poorest countries know this all too well. It s a fact few people in wealthier nations realize. Rotavirus
More informationGlaxoSmithKline Biologicals Rotarix WHO PACKAGE INSERT. Rotarix TM 1 WHO Package insert
GlaxoSmithKline Biologicals Rotarix WHO PACKAGE INSERT Rotarix TM 1 WHO Package insert GlaxoSmithKline Biologicals Rotarix Method of administration Rotarix is for oral use only. ROTARIX SHOULD UNDER NO
More informationIntroduction and overview of the program; new vaccine pipeline and prioritization process
Immunization for the Modern Family: Western Canada Immunization Forum 2011 Introduction and overview of the program; new vaccine pipeline and prioritization process Monika Naus, MD, MHSc, FRCPC, FACPM
More informationRotavirus Vaccine. Supply and Procurement Roadmap. The Market Shaping Goal. Public Summary. Rotavirus Supply and Procurement Roadmap UPDATE 2016
The Market Shaping Goal Shape markets for vaccines and other immunisation products to achieve moderate or high levels of healthy markets dynamics. Supply and Procurement Roadmap Rotavirus Vaccine Public
More informationFecal shedding of rotavirus vaccine in premature babies in the neonatal unit
Fecal shedding of rotavirus vaccine in premature babies in the neonatal unit Dr. Manish Sadarangani Director, Vaccine Evaluation Center, BC Children s Hospital Research Institute Assistant Professor, Division
More informationVaccines. Global impact of a preventive technology. Edwin J. Asturias, MD
Vaccines Global impact of a preventive technology Edwin J. Asturias, MD Associate Professor of Pediatrics and Epidemiology Director for Latin America Center for Global Health, Colorado School of Public
More informationRotarix TM. Rotavirus vaccine
Rotarix TM Rotavirus vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (1.5 ml) contains: Live attenuated human rotavirus RIX4414 strain* of the G1P[8] type: not less than 10 6.0 CCID 50 *Produced
More informationInterference of Monovalent, Bivalent, and Trivalent Oral Poliovirus Vaccines on Monovalent Rotavirus Vaccine Immunogenicity in Rural Bangladesh
Clinical Infectious Diseases Advance Access published October 9, 2015 MAJOR ARTICLE Interference of Monovalent, Bivalent, and Trivalent Oral Poliovirus Vaccines on Monovalent Rotavirus Vaccine Immunogenicity
More informationApproaches to Assessing Intussusception Risk in Developing Countries
Approaches to Assessing Intussusception Risk in Developing Countries Jacqueline Tate Centers for Disease Control and Prevention Atlanta, GA, USA National Center for Immunization & Respiratory Diseases
More informationImpact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries
August 29, 2018 Impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries Thirteenth International Rotavirus Symposium 29 31 August 2018 Minsk, Belarus Frédéric Debellut Health Economist,
More informationInfluenza immunization in pregnancy: observations in mother, fetus, infant
Influenza immunization in pregnancy: observations in mother, fetus, infant Mark C. Steinhoff, MD Director, Global Health Center Professor of Pediatrics Cincinnati Children s Hospital Medical Center Cincinnati
More informationConclusions and Recommendations of the Experts Meeting on Rotavirus Genotypes in the Region of the Americas
Conclusions and Recommendations of the Experts Meeting on Rotavirus Genotypes in the Region of the Americas Eyal Leshem December 9, 2013 National Center for Immunization & Respiratory Diseases Division
More informationANNUAL REPORT We believe in a world where every woman and girl has the right and ability to determine her own sexuality and reproductive health.
ANNUAL REPORT 2016 We believe in a world where every woman and girl has the right and ability to determine her own sexuality and reproductive health. 22 MILLION UNSAFE ABORTIONS EACH YEAR WE RE WORKING
More informationMeasles Containing Vaccines. UNICEF Supply Division Industry Consultation Meeting January 2012
Measles Containing Vaccines UNICEF Supply Division Industry Consultation Meeting 25-26 January 2012 Content Measles monovalent vaccine: Programme Updates and Procurement Overview Measles and Rubella vaccine:
More informationExisting approaches to costing, financing and estimating cost-efficiencies for nutrition
Existing approaches to costing, financing and estimating cost-efficiencies for nutrition February 2016 Meera Shekar Global Lead for Nutrition 1 Global Stunting Rates 159 million children stunted worldwide
More informationIMPORTANCE OF VACCINE PREVENTABLE DISEASE INCIDENCE. Bradford D. Gessner, MD Agence de Médecine Preventive
IMPORTANCE OF VACCINE PREVENTABLE DISEASE INCIDENCE Bradford D. Gessner, MD Agence de Médecine Preventive Vaccine Launches 2013 2 Disease burden has been consistently mentioned by policymakers in countries
More informationCorrelates of protection for rotavirus vaccines: Possible alternative trial endpoints, opportunities, and challenges
Human Vaccines & Immunotherapeutics 10:12, 3659--3671; December 2014; Published with license by Taylor & Francis Group, LLC REVIEW Correlates of protection for rotavirus vaccines: Possible alternative
More informationA NEW PARADIGM FOR TRANSLATIONAL VACCINE DEVELOPMENT. Introducing the Gates Medical Research Institute
A NEW PARADIGM FOR TRANSLATIONAL VACCINE DEVELOPMENT Introducing the Gates Medical Research Institute MY JOURNEY A NEW PARADIGM FOR TRANSLATIONAL VACCINE DEVELOPMENT Introducing the Gates Medical Research
More informationDevelopment of a heat-stable Rotavirus vaccine using innovative delivery technology
Development of a heat-stable Rotavirus vaccine using innovative delivery technology 1 HILLEMAN OPERATING MODEL IS UNIQUE WITH FOCUS ON TRANSLATIONAL SCIENCE AND GETTING AFFORDABLE VACCINES TO MARKET FASTER
More informationGSK VACCINES: KEY GROWTH DRIVERS
GSK VACCINES: KEY GROWTH DRIVERS Martin Andrews Senior Vice President, Global Vaccines Centre of Excellence, GSK Biologicals Millions of children die from infectious diseases Many of these deaths are preventable
More informationGlobal Health Policy: Vaccines
Global Health Policy: Vaccines Edwin J. Asturias Senior Investigator Colorado School of Public Health Department of Pediatrics Children s Hospital Colorado UNIVERSITY OF COLORADO COLORADO STATE UNIVERSITY
More informationDevelopment of a Group A meningococcal conjugate vaccine for sub-saharan Africa: clinical trial results
Development of a Group A meningococcal conjugate vaccine for sub-saharan Africa: clinical trial results Global Immunization Meeting 2009, United Nations HQ New York City, February 2009 MenA conjugate vaccine
More informationGlobal landscape analysis and literature review of 2 nd Year of Life immunization platform
Global landscape analysis and literature review of 2 nd Year of Life immunization platform Global Vaccine and Immunization Research Forum 15-17 March 2016 Johannesburg, South Africa Imran Mirza; Celina
More informationRotarix TM. Rotavirus vaccine
Rotarix TM Rotavirus vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution, 1 dose (1 ml) contains: Live attenuated human rotavirus RIX4414 strain not less than 10 6.0 CCID 50 PHARMACEUTICAL
More informationTHE ROLE OF DISEASE BURDEN IN THE DECISION MAKING PROCESS: THE HIB VACCINE EXPERIENCE. Brad Gessner, MD Agence de Médecine Preventive
THE ROLE OF DISEASE BURDEN IN THE DECISION MAKING PROCESS: THE HIB VACCINE EXPERIENCE Brad Gessner, MD Agence de Médecine Preventive INDUSTRIALIZED COUNTRIES Meningitis incidence per 1 0 0 K per year 1970s:
More informationGOAL 2: ACHIEVE RUBELLA AND CRS ELIMINATION. (indicator G2.2) Highlights
GOAL 2: ACHIEVE RUBELLA AND CRS ELIMINATION (indicator G2.2) Highlights As of December 2014, 140 Member States had introduced rubella vaccines; coverage, however, varies from 12% to 94% depending on region.
More informationNational Immunisation Programme changes Michael Baker. Wessex Public Health England Centre
National Immunisation Programme changes 2013-14 Michael Baker Wessex Public Health England Centre Changes to the Meningococcal serogroup C conjugate (MenC) vaccine schedule in 2013 2 Immunisation Programme
More informationUpdate from GAVI Aurelia Nguyen
Update from GAVI Aurelia Nguyen (Copenhagen, Denmark, 27 June 2012) GAVI vaccine support Currently supported vaccines: pentavalent, pneumococcal, rotavirus, meningitis A, human papillomavirus (HPV), rubella,
More informationCase study: Evaluation of Rotavirus vaccine impact and safety following introduction into the national immunizations programme of Sudan
15 th ADVAC Case study Rota in Sudan Case study: Evaluation of Rotavirus vaccine impact and safety following introduction into the national immunizations programme of Sudan Background Rotavirus is one
More informationMARKET UPDATE: ROUTINE VACCINE INTRODUCTIONS PCV HPV ROTA
UNICEF/UN074388/LeMoyne MARKET UPDATE: ROUTINE VACCINE INTRODUCTIONS PCV HPV ROTA Vaccine Industry Consultation October 2018 Pneumococcal Conjugate Vaccine (PCV) Background The AMC initiative has opened
More informationSummary of WHO Position on Rotavirus. Narendra K. Arora SAGE Member Executive Director The INCLEN Trust International New Delhi (India)
Summary of WHO Position on Rotavirus Narendra K. Arora SAGE Member Executive Director The INCLEN Trust International New Delhi (India) Presentation WHO Position Papers on Rotavirus Optimizing immunization
More informationIX. IMPROVING MATERNAL HEALTH: THE NEED TO FOCUS ON REACHING THE POOR. Eduard Bos The World Bank
IX. IMPROVING MATERNAL HEALTH: THE NEED TO FOCUS ON REACHING THE POOR Eduard Bos The World Bank A. INTRODUCTION This paper discusses the relevance of the ICPD Programme of Action for the attainment of
More informationGAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS
GAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS Ranjana Kumar International Rotavirus Symposium Istanbul, 3 4 June 2008 The GAVI Alliance Public-private partnership bringing
More information5th Meeting of the Initiative against Diarrheal & Enteric diseases in Asia IDEA
5th Meeting of the Initiative against Diarrheal & Enteric diseases in Asia IDEA Firdausi Qadri icddr,b Country Situation Update: Bangladesh Hanoi, Vietnam 7th March 2017 1 [Insert presentation title] 2
More informationTo Tie the Knot or Not: A Case for Permanent Family Planning Methods
To Tie the Knot or Not: A Case for Permanent Family Planning Methods Presented at the GH Mini-University Washington, D.C., October 8, 2010 By Lynn Bakamjian, MPH Project Director, RESPOND/EngenderHealth
More informationBRIEFING ON RTS,S/AS01 MALARIA VACCINE FOR THE SEPTEMBER 2012 MEETING OF MPAC
BRIEFING ON RTS,S/AS01 MALARIA VACCINE FOR THE SEPTEMBER 2012 MEETING OF MPAC Introduction Date: 12 August 2012. Author: WHO Secretariat with input from JTEG Chair The most advanced vaccine candidate against
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationReport from the Pertussis Working Group
Report from the Pertussis Working Group Elizabeth Miller SAGE Member and Chair of the Pertussis Working Group 29 October 2009 Geneva Working Group Members Elizabeth Miller (chair), Health Protection Agency,
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Rotarix powder and solvent for oral suspension Rotavirus vaccine, live 2. QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution,
More informationVaccines. Global impact of a preventive technology. Edwin J. Asturias, MD
Vaccines Global impact of a preventive technology Edwin J. Asturias, MD Associate Professor of Pediatrics and Epidemiology Director for Latin America Center for Global Health, Colorado School of Public
More informationImpact of Rotavirus Vaccination on Diarrheal Hospitalizations in Children Aged <5 Years in Lusaka, Zambia
Clinical Infectious Diseases SUPPLEMENT ARTICLE Impact of Rotavirus Vaccination on Diarrheal Hospitalizations in Children Aged
More informationSafety and Immunogenicity of a Parenterally Administered Rotavirus VP8 Subunit Vaccine in Healthy Adults
Safety and Immunogenicity of a Parenterally Administered Rotavirus VP8 Subunit Vaccine in Healthy Adults Stanley Cryz 1, Clayton Harro 2, Monica McNeal 3, Nicole Meyer 3, Barbara DeNearing 2, Alicia Cage
More informationRecipients of development assistance for health
Chapter 2 Recipients of development assistance for health Both low- and middle-income countries are eligible for development assistance for health (DAH). In addition to income, burden of disease, which
More informationHPV Vaccine Lessons Learned & New Ways Forward
HPV Vaccine Lessons Learned & New Ways Forward The Gavi Alliance June 2016, Geneva www.gavi.org Overview 1 Background 2 Lessons learned 3 New Way Forward 2 1 Background 3 HPV Background HPV is responsible
More informationThe Gates Challenge. Bill Gates Commencement Address Harvard University Class of 2007
History & Future of the Expanded Programme on Immunization Supplier Meeting, Copenhagen, 3-4 April 2008 Dr Osman David Mansoor Senior Adviser EPI (New Vaccines) UNICEF New York The Gates Challenge If we
More informationUpdated WHO position paper on pertussis vaccines. Geneva, Switzerland October 2010
Updated WHO position paper on pertussis vaccines Geneva, Switzerland October 2010 Introduction Replaces the position paper on pertussis vaccines published in the Weekly Epidemiological Record in January
More informationVaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV
Supplemental Digital Content 1. Methodology Inclusion and exclusion criteria Eligible participants were infants between and including 6 10 weeks of age at the time of the first vaccination, who were free
More informationGlobal Consultation on Child and Adolescent Health and Development 13 March 2002 Stockholm, Sweden
Global Consultation on Child and Adolescent Health and Development 12-13 13 March 2002 Stockholm, Sweden Mdm. Bruntland Says: 11 million children die each year 8 million can be averted each year Each decade
More informationPROGRESS REPORT ON CHILD SURVIVAL: A STRATEGY FOR THE AFRICAN REGION. Information Document CONTENTS
29 June 2009 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Fifty-ninth session Kigali, Republic of Rwanda, 31 August 4 September 2009 Provisional agenda item 9.2 PROGRESS REPORT ON CHILD SURVIVAL: A
More informationAccelerating the Introduction of Rotavirus Vaccines into GAVI-Eligible Countries
Accelerating the Introduction of Rotavirus Vaccines into GAVI-Eligible Countries Investment Case for GAVI Secretariat Submitted by PATH s Rotavirus Vaccine Program in collaboration with WHO and the US
More informationSummary of Key Points
Summary of Key Points WHO Position Paper on Vaccines against Pertussis September 2015 1 Background l Pertussis (whooping cough), caused by the bacterium Bordetella pertussis, was one of the most common
More informationA Call to Action Children The missing face of AIDS
A Call to Action Children The missing face of AIDS Scaling up Paediatric HIV Care Treatment in resource limited settings Dr Chewe Luo MMed(Paed); MTropPaed; PhD UNICEF Health Section Programme Division
More informationOkinawa, Toyako, and Beyond: Progress on Health and Development
Okinawa, Toyako, and Beyond: Progress on Health and Development Prof. Michel D. Kazatchkine Executive Director The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations University, Tokyo,
More informationNoninterference of Rotavirus Vaccine With Measles- Rubella Vaccine at 9 Months of Age and Improvements in Antirotavirus Immunity: A Randomized Trial
The Journal of Infectious Diseases MAJOR ARTICLE Noninterference of Rotavirus Vaccine With Measles- Rubella Vaccine at 9 Months of Age and Improvements in Antirotavirus Immunity: A Randomized Trial K.
More informationPolio vaccines and polio immunization in the pre-eradication era: WHO position paper. Published in WER 4 June, 2010
Polio vaccines and polio immunization in the pre-eradication era: WHO position paper Published in WER 4 June, 2010 Epidemiology & Background Poliomyelitis (polio) is an acute communicable disease of humans
More informationFor the use only of registered medical practitioners or a hospital or a laboratory ROTARIX. Rotavirus Vaccine (Live Attenuated, Oral) IP
For the use only of registered medical practitioners or a hospital or a laboratory ROTARIX Rotavirus Vaccine (Live Attenuated, Oral) IP 1. NAME OF THE MEDICINAL PRODUCT Rotavirus Vaccine (Live Attenuated,
More information